/2561 August 7, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q2/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
period of 2019 To : The President of the Stock Exchange of Thailand The Company would like to provide details of changes in Profit and Loss as shown in the six-month period ending 30 June 2020 reviewed
Securities and Exchange Commission No. Sor Thor. 29/2559 Re: Rules in Detail on Financial Resource and Risk Management of Securities Clearing Houses ________________________ By virtue of Clause 5 (1), in
Securities and Exchange Commission No. Sor Thor. 30/2559 Re: Rules in Detail on Financial Resource and Risk Management of Derivatives Clearing Houses ________________________ By virtue of Clause 5 (1), in
Extraordinary General Meeting of the Shareholders No. 1/2561, Plans for listing CAZ (Thailand) Co., Ltd. on the Stock Exchange of Thailand Attention The President The Stock Exchange of Thailand Enclosure
the Securities and Exchange Act B.E. 2535 (1992) , as amended by the Securities and Exchange Act (No. 4) B.E. 2551 (2008) , and Section 114 of the Securities and Exchange Act B.E. 2535 (1992) , which
Securities and Exchange Act B.E. 2535 (1992), as amended by the Securities and Exchange Act (No. 4) B.E. 2551 (2008), and Section 114 of the Securities and Exchange Act B.E. 2535 (1992), which contain certain
comparing to Q4/2018 loss of Baht 143 million due to higher utilization rate as well as tight costs and expenses control. EBITDA in Q1/2019 was Baht 9 million, a decline of 88% YoY but an 107% upturn QoQ
No. CAZ 017/2020 07 August 2020 Subject: Management Discussion and Analysis for the 2nd Quarter ended 30 June 2020 Attention: The President, The Stock Exchange of Thailand CAZ (Thailand) Public